Literature DB >> 9622380

Reduced immunoreactivity of type I adenylyl cyclase in the postmortem brains of alcoholics.

E Hashimoto1, L Frölich, H Ozawa, T Saito, K Maurer, J Böning, N Takahata, P Riederer.   

Abstract

Reduced adenylyl cyclase activity after chronic ethanol exposure has been reported. In this study, we investigated by immunoblotting whether quantitative changes of adenylyl cyclase isoforms (type I, type II, and type V/VI adenylyl cyclases) exist in membrane preparations of the temporal cortex obtained from six alcoholics and six age-matched controls. The immunoreactivity of type I adenylyl cyclase decreased significantly in the temporal cortex of alcoholics when compared with controls (p < 0.05), whereas those of type II and type V/VI adenylyl cyclases showed no changes between the groups. These findings suggest that these isoform-specific afterations in the adenylyl cyclase system may be involved in the pathophysiology of alcoholism.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9622380     DOI: 10.1111/acer.1998.22.s3_part1.88s

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  4 in total

1.  Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers.

Authors:  Bruce T Hope; Deepti Nagarkar; Sherry Leonard; Roy A Wise
Journal:  J Neurosci       Date:  2007-02-21       Impact factor: 6.167

Review 2.  Cyclic nucleotide phosphodiesterases: potential therapeutic targets for alcohol use disorder.

Authors:  Rui-Ting Wen; Fang-Fang Zhang; Han-Ting Zhang
Journal:  Psychopharmacology (Berl)       Date:  2018-04-16       Impact factor: 4.530

3.  Real-time monitoring of intracellular cAMP during acute ethanol exposure.

Authors:  Ratna Gupta; Emily Qualls-Creekmore; Masami Yoshimura
Journal:  Alcohol Clin Exp Res       Date:  2013-06-03       Impact factor: 3.455

4.  Transcriptional changes common to human cocaine, cannabis and phencyclidine abuse.

Authors:  Elin Lehrmann; Carlo Colantuoni; Amy Deep-Soboslay; Kevin G Becker; Ross Lowe; Marilyn A Huestis; Thomas M Hyde; Joel E Kleinman; William J Freed
Journal:  PLoS One       Date:  2006-12-27       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.